With Renvela, Genzyme Wants To Grow Market, But Not Necessarily Share
Executive Summary
Genzyme will manage the launch of Renvela (sevelamer carbonate) in the first quarter of 2008 to grow the brand and the market, Renal Division President John Butler told analysts during the company's Oct. 24 earnings call
You may also be interested in...
Genzyme Sets Sights On 13 Drug Approvals By 2012
To reach a goal of compound annual growth of 20 percent in the five-year period from 2006 to 2011, Genzyme will rely on new products and label expansions to drive growth, CEO Henri Termeer said during the company's annual analyst and investor day May 7
Genzyme Sets Sights On 13 Drug Approvals By 2012
To reach a goal of compound annual growth of 20 percent in the five-year period from 2006 to 2011, Genzyme will rely on new products and label expansions to drive growth, CEO Henri Termeer said during the company's annual analyst and investor day May 7
Phosphate Binders Need To Show Clinical Benefit For Pre-Dialysis – Cmte.
Outcomes trials should be conducted to support the approval of phosphate binders for use in the pre-dialysis setting for kidney disease patients, FDA's Cardiovascular and Renal Drugs Advisory Committee concluded Oct. 16